Current and emerging pharmacotherapy for the treatment of bacterial peritonitis
Alberto Enrico Maraolo1, Ivan Gentile1, Biagio Pinchera1
1a Department of Clinical Medicine and Surgery, Section of Infectious Diseases , University of Naples Federico II , Naples , Italy.
Introduction:
Spontaneous bacterial peritonitis (SBP) is the quintessential model of bacterial infection in cirrhotic patients. In these particularly frail subjects, infections clearly worsen prognosis increasing substantially mortality. Furthermore, treatment of SBP has become more challenging because of the growing impact of multidrug-resistant (MDR) bacteria.
Areas Covered:
This review addresses the reasons behind the change in therapeutic recommendations for SBP that have occurred in the past few years, by focusing on the following aspects: the importance of an early appropriate empirical treatment, the difference between nosocomial and non-nosocomial forms and the overall microbiological shift (rise of Gram-positive bacteria and MDR strains) that have affected SBP.
Expert Opinion:
Until recently, third-generation cephalosporins have represented the cornerstone of SBP treatment, a safe choice covering the most important causative agents, namely Enterobacteriaceae. Unfortunately, massive exposure to health systems makes cirrhotic patients prone to MDR infections, which poses significant challenges, all the while not forgetting to strike a balance between effective antimicrobial activity and the risk of toxicity in these fragile subjects. Moreover, there is sparse information about new antibiotics in cirrhotic patients and about drugs levels in ascitic fluid. Therefore, further research is needed to optimize the treatment of SBP.
Insights
Spontaneous bacterial peritonitis (SBP) treatment is challenged by multidrug-resistant (MDR) bacteria in cirrhotic patients. New therapeutic strategies are needed to address the evolving microbiology and improve patient outcomes.
Area of Science:
- Hepatology
- Infectious Diseases
- Clinical Microbiology
Background:
- Spontaneous bacterial peritonitis (SBP) is a severe complication in cirrhotic patients, significantly increasing mortality.
- The rise of multidrug-resistant (MDR) bacteria complicates SBP treatment, necessitating updated therapeutic approaches.
- Cirrhotic patients are vulnerable to healthcare-associated infections due to frequent health system exposure.
Purpose of the Study:
- To review changes in SBP therapeutic recommendations.
- To analyze the impact of microbiological shifts, including MDR strains, on SBP treatment.
- To highlight the need for optimized antimicrobial strategies in cirrhotic patients with SBP.
Main Methods:
- Literature review focusing on SBP treatment guidelines and microbiological trends.
- Analysis of the evolving landscape of SBP causative agents, particularly Gram-positive bacteria and MDR strains.
- Evaluation of current therapeutic options and their limitations in cirrhotic patients.
Main Results:
- Third-generation cephalosporins, previously standard, are less effective against emerging MDR pathogens.
- Distinguishing between nosocomial and non-nosocomial SBP is crucial for appropriate empirical treatment.
- There is a critical need for research on novel antibiotics and their pharmacokinetics in ascitic fluid.
Conclusions:
- Current SBP treatment strategies require re-evaluation due to increasing MDR bacteria.
- Early, appropriate empirical treatment tailored to local resistance patterns is essential.
- Further research is imperative to develop safer and more effective SBP therapies for fragile cirrhotic patients.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Emerging Adulthood
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Introduction Cardiac Emergencies
Electrical Current


